Table 3 Response and MRD-negativity rates in patients with standard and high cytogenetic risk.

From: Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

 

Standard risk

High risk*

Response,† n (%)

D-Rd (n = 190)

Rd (n = 172)

P

D-Rd (n = 35)

Rd (n = 34)

P

ORR

178 (94)

135 (79)

<0.0001

31 (89)

23 (68)

0.0145

 ≥CR

111 (58)

43 (25)

 

15 (43)

3 (9)

 

  Stringent CR

61 (32)

23 (13)

 

10 (29)

1 (3)

 

  CR

50 (26)

20 (12)

 

5 (14)

2 (6)

 

 ≥VGPR

156 (82)

92 (54)

<0.0001

25 (71)

10 (29)

0.0004

  VGPR

45 (24)

49 (29)

 

10 (29)

7 (21)

 

 PR

22 (12)

43 (25)

 

6 (17)

13 (38)

 

MRD negative (10–5)‡

n = 193

n = 176

 

n = 35

n = 35

 

 n (%)

63 (33)

15 (9)

<0.0001

9 (26)

0

0.0022

 Sustained MRD negativity (≥6 months), n (%)

35 (18)

2 (1)

<0.0001

1 (3)

0

 

 Sustained MRD negativity (≥12 months), n (%)

27 (14)

1 (1)

<0.0001

1 (3)

0

 
  1. MRD minimal residual disease, D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, ORR overall response rate, CR complete response, VGPR very good partial response, PR partial response, ITT intent-to-treat.
  2. *Patients with high cytogenetic risk had a t(4;14), t(14;16), or del17p abnormality.
  3. †Response-evaluable population.
  4. ‡ITT population.
Back to article page